| # | Title | Journal | Year | Citations |
|---|
| 1 | Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer | JAMA Oncology | 2021 | 92 |
| 2 | Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials | Journal of Clinical Oncology | 2021 | 84 |
| 3 | Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment | European Journal of Cancer | 2022 | 76 |
| 4 | Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients | Annals of Oncology | 2021 | 68 |
| 5 | Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial | Clinical Cancer Research | 2019 | 65 |
| 6 | Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer | Journal of the National Cancer Institute | 2021 | 56 |
| 7 | Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers | | 2022 | 45 |
| 8 | RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study | | 2020 | 43 |
| 9 | Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer | ESMO Open | 2021 | 42 |
| 10 | Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: aPost HocAnalysis of the PRODIGE-GERCOR IDEA-France Trial | Clinical Cancer Research | 2021 | 42 |
| 11 | Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer | European Journal of Cancer | 2021 | 40 |
| 12 | Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study. | Journal of Clinical Oncology | 2022 | 39 |
| 13 | High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers | Annals of Oncology | 2021 | 38 |
| 14 | Prognostic value and characteristics of N1c colorectal cancer | Colorectal Disease | 2018 | 32 |
| 15 | Comprehensive integrative profiling of upper tract urothelial carcinomas | Genome Biology | 2021 | 31 |
| 16 | A new prognostic and predictive tool for shared decision making in stage III colon cancer | European Journal of Cancer | 2020 | 27 |
| 17 | Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects? | Aids | 2020 | 25 |
| 18 | ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer | Journal of Clinical Oncology | 2023 | 25 |
| 19 | Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database | Annals of Oncology | 2020 | 23 |
| 20 | Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers | Scientific Reports | 2020 | 21 |
| 21 | Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group | Annals of Oncology | 2020 | 20 |
| 22 | ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016 | Annals of Oncology | 2016 | 18 |
| 23 | BRAFV600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database | Journal of the National Cancer Institute | 2021 | 17 |
| 24 | HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: A review | Critical Reviews in Oncology/Hematology | 2013 | 16 |
| 25 | Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative | European Journal of Cancer | 2020 | 15 |
| 26 | Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer | | 2021 | 15 |
| 27 | Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer:Post hocAnalysis of the MOSAIC and PETACC-8 Trials | Cancer Epidemiology Biomarkers and Prevention | 2019 | 14 |
| 28 | Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors | Lung Cancer | 2021 | 14 |
| 29 | Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients | Cancers | 2021 | 13 |
| 30 | The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe | ESMO Open | 2016 | 12 |
| 31 | Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective | Breast | 2017 | 12 |
| 32 | Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer | Journal of the National Cancer Institute | 2021 | 12 |
| 33 | Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer | Cancers | 2021 | 12 |
| 34 | One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study. | Journal of Clinical Oncology | 2022 | 12 |
| 35 | Integrative Medicine in Interventional Oncology: A Virtuous Alliance | Medicina (Lithuania) | 2020 | 11 |
| 36 | Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment | Molecular Oncology | 2021 | 11 |
| 37 | Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer | Cancers | 2022 | 11 |
| 38 | Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer | Cancer Treatment Reviews | 2022 | 10 |
| 39 | Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials | Journal of Clinical Oncology | 2023 | 10 |
| 40 | Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group | Journal of Thoracic Oncology | 2016 | 9 |
| 41 | BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors | Oncologist | 2023 | 7 |
| 42 | Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials. | Journal of Clinical Oncology | 2022 | 6 |
| 43 | Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients | Clinical Colorectal Cancer | 2021 | 5 |
| 44 | Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials | Journal of the National Cancer Institute | 2022 | 5 |
| 45 | Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer. | Journal of Clinical Oncology | 2022 | 5 |
| 46 | Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group | Clinics and Research in Hepatology and Gastroenterology | 2021 | 3 |
| 47 | Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR/MSI-H colorectal cancer, a BIG-RENAPE collaboration | Digestive and Liver Disease | 2022 | 3 |
| 48 | Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC). | Journal of Clinical Oncology | 2021 | 2 |
| 49 | Genetic landscape of indolent and aggressive Kaposi sarcomas | Journal of the European Academy of Dermatology and Venereology | 0 | 2 |
| 50 | Impact of Lynch syndrome, BRAFV600E, and RAS mutations on outcomes in MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Analysis of combined international cohorts. | Journal of Clinical Oncology | 2023 | 2 |
